Drug intelligence / Profile preview

darceline

Development stage: Preclinical
Lead developer: Yunnan Cancer Hospital and Affiliated Cancer Hospital of Guangxi Medical University
Administration: Oral

Overview

Darceline is an investigational pharmaceutical drug being studied for the treatment of breast cancer. Clinical trials are exploring its use in ER+/HER2+ early breast cancer and HR+ advanced breast cancer. It is administered orally, with a typical regimen involving continuous daily dosing for three weeks followed by a one-week rest period within a 28-day cycle. The specific mechanism of action for darceline has not been disclosed in the available information.

Other names: Dalxil

Beyond the preview

Go deeper on darceline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on darceline.

Explore the full profile